ORIC Oric Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1796280 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-15.2%
TTM EPS YoY15.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.8%
ROA-39.1%
ROIC (approx.)-40.8%
Asset turnover—
Leverage & solvency
Liabilities / assets7.5%
Debt / equity0.00x
Current ratio11.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $43.36M | $36.30M | $31.44M | $25.86M | $28.77M | $30.55M | $24.64M | $31.97M |
| SG&A expense | $8.19M | $9.00M | $8.18M | $8.70M | $7.90M | $8.52M | $8.08M | $7.60M |
| Operating income | -$51.55M | -$45.30M | -$39.62M | -$34.55M | -$36.67M | -$39.06M | -$32.72M | -$39.57M |
| Net income | -$48.08M | -$41.49M | -$35.77M | -$30.50M | -$32.59M | -$36.35M | -$30.02M | -$36.31M |
| EBITDA | -$51.27M | -$45.03M | -$39.35M | -$34.23M | -$36.38M | -$38.75M | -$32.42M | -$39.27M |
| EPS (basic) | -0.44 | -0.38 | -0.34 | — | -0.33 | -0.47 | -0.42 | — |
| EPS (diluted) | -0.44 | -0.38 | -0.34 | — | -0.33 | -0.47 | -0.42 | — |
| Weighted avg. shares (diluted) | 108.18M | 108.01M | 105.47M | — | 98.95M | 78.13M | 71.04M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $33.85M | $37.48M | $56.40M | $45.67M | $49.67M | $75.86M | $49.33M | $59.90M |
| Short-term investments | $227.53M | $227.28M | $225.54M | $235.82M | $237.47M | $206.65M | $154.39M | $196.55M |
| Current assets | $274.75M | $273.69M | $290.23M | $288.47M | $295.59M | $291.12M | $211.43M | $262.25M |
| PP&E, net | $2.08M | $2.24M | $2.15M | $2.42M | $2.56M | $2.76M | $3.02M | $2.92M |
| Total assets | $366.89M | $404.69M | $436.76M | $408.89M | $431.19M | $346.86M | $242.86M | $274.14M |
| Current liabilities | $24.78M | $20.76M | $17.77M | $20.42M | $20.18M | $18.05M | $17.62M | $24.85M |
| Total liabilities | $27.38M | $23.43M | $21.20M | $24.53M | $24.27M | $22.86M | $23.12M | $31.02M |
| Shareholders' equity | $339.50M | $381.26M | $415.56M | $384.36M | $406.92M | $324.00M | $219.74M | $243.12M |
| Shares outstanding | 103.87M | 103.64M | 103.49M | 98.53M | 97.28M | 86.19M | 71.08M | 71.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$41.99M | -$31.61M | -$32.44M | -$22.48M | -$25.11M | -$30.84M | -$32.53M | -$28.05M |
| Capital expenditure | $107,000 | $356,000 | $2,000 | $227,000 | $35,000 | $63,000 | $387,000 | $219,000 |
| Free cash flow | -$42.09M | -$31.96M | -$32.44M | -$22.71M | -$25.15M | -$30.91M | -$32.92M | -$28.27M |
| Investing cash flow | $37.54M | $11.86M | -$17.98M | $16.98M | -$110.53M | -$76.93M | $22.45M | $42.66M |
| Financing cash flow | $806,000 | $828,000 | $61.14M | $1.50M | $109.45M | $134.30M | $11,000 | $575,000 |
| Depreciation & amortization | $279,000 | $264,000 | $270,000 | $320,000 | $288,000 | $310,000 | $302,000 | $304,000 |
| Stock-based compensation | $6.19M | $7.09M | $6.90M | $6.28M | $5.63M | $6.57M | $6.55M | $5.20M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.